Regeneron Pharmaceuticals

Antibody biotech behind Eylea and Dupixent. Its GLP-1 exposure is complementary rather than competitive: the Phase 2 COURAGE trial adds trevogrumab (anti-myostatin), with or without garetosmab, on top of semaglutide to protect lean mass. At 26 weeks the combination prevented roughly half the lean-mass loss seen with semaglutide alone.